Bayer AG stock (DE000BAY0017): S&P affirms BBB rating with negative outlook

S&P Global Ratings affirmed Bayer AG's 'BBB' long-term foreign currency credit rating on May 8, 2026, with a negative outlook. The stock trades as BAYRY on US OTC markets.

S&P Global Ratings affirmed Bayer AG's 'BBB' long-term foreign currency credit rating on May 8, 2026, maintaining a negative outlook, as reported by Cbonds on May 8, 2026. This decision reflects ongoing challenges in the company's pharmaceutical and crop science divisions amid litigation risks and market pressures. Bayer AG, traded as BAYRY on US OTC markets, closed at $8.55 on July 25, 2025, up 0.588% that day according to StockInvest.us as of July 25, 2025.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bayer AG
• Sector/industry: Pharmaceuticals, Crop Science, Consumer Health
• Headquarters/country: Germany
• Core markets: North America, Europe, Asia
• Key revenue drivers: Pharmaceuticals, Agriculture
• Home exchange/listing venue: Xetra (BAYN.DE), OTC (BAYRY)
• Trading currency: EUR (primary), USD (ADR)

Bayer AG: core business model

Bayer AG operates as a life sciences company with three main divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on prescription drugs in cardiology, oncology, and women's health. Crop Science provides seeds, crop protection products, and digital farming solutions. Consumer Health includes non-prescription products like pain relief and skincare. This diversified model targets global healthcare and agriculture markets, with significant exposure to US consumers and farmers.

Headquartered in Leverkusen, Germany, Bayer AG generates substantial revenue from North America, which accounts for a key portion of its sales. The company's ADR (BAYRY) allows US investors direct access on OTC markets.

Main revenue and product drivers for Bayer AG

Pharmaceuticals drive growth through blockbuster drugs like Xarelto (blood thinner) and Eylea (eye disease treatment), though patent expirations pose risks. Crop Science benefits from genetically modified seeds and pesticides, amid US farmer demand. Recent dividend payments include $0.0200 per ADR ex-date April 29, 2025, yielding 0.303%, per StockInvest.us dividend history. US agriculture exposure ties Bayer to corn belt economics.

Industry trends and competitive position

Bayer AG competes with Pfizer, Novartis in pharma and Corteva, Syngenta in agribusiness. ESG trends favor its crop science innovations like camelina for biofuels. A partnership with bp to commercialize camelina in North America for renewable diesel and SAF was announced, building on Bayer's January 2025 asset acquisition, per ESG News. This positions Bayer in US sustainable fuel markets.

Why Bayer AG matters for US investors

Bayer AG's BAYRY ADR offers US retail investors exposure to European life sciences with strong US revenue ties. Its crop science division serves American farmers, while pharma products reach US patients. Credit rating stability amid negative outlook signals monitoring debt and litigation for portfolio diversification.

Conclusion

The S&P affirmation of Bayer AG's BBB rating with negative outlook underscores persistent challenges, balanced by strategic moves like the bp camelina partnership targeting US biofuels. Recent BAYRY price gains and dividends provide context, though litigation overhangs remain. Investors track upcoming earnings and regulatory developments for clarity on the trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.